CLINICAL_TRIALS
trial_result
· 2026-03-19
Clinical Trial Update: GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) [Phase 2, Phase 3]
Summary
Pfizer's GBT021601 study in sickle cell disease (Phase 2/3) has been terminated and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Sickle Cell Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2026-03-19